Abstract | BACKGROUND: OBJECTIVES: PATIENTS AND METHODS: The subjects were 60 female patients on maintenance hemodialysis (non-diabetic, n=30; diabetic, n=30). Raloxifene hydrochloride (60 mg) was administered to 14 diabetic patients and 14 non-diabetic patients for one year, and these patients were compared with control groups (no raloxifene) of 16 diabetic patients and 16 non-diabetic patients. Serum levels of N-terminal cross-linking telopeptide of type I collagen (NTx), bone alkaline phosphatase, and intact parathyroid hormone (iPTH) were measured, and bone density was determined by quantitative heel ultrasound at the speed of sound (SOS) in the calcaneus during this period. RESULTS: There were no significant differences in the levels of bone turnover markers except for iPTH after treatment of diabetic and non-diabetic patients with raloxifene for one year. SOS increased after treatment with raloxifene, but was significantly decreased in the control groups. Treatment with raloxifene resulted in a significant decrease in NTx and a significant increase in SOS in both diabetic and non-diabetic patients. There were no significant differences between the diabetic and non-diabetic patients who received raloxifene. CONCLUSIONS:
|
Authors | Osamu Saito, Takako Saito, Shinji Asakura, Tetsu Akimoto, Makoto Inoue, Yasuhiro Ando, Shigeaki Muto, Eiji Kusano |
Journal | International journal of endocrinology and metabolism
(Int J Endocrinol Metab)
Vol. 10
Issue 2
Pg. 464-9
( 2012)
ISSN: 1726-913X [Print] Netherlands |
PMID | 23843805
(Publication Type: Journal Article)
|